Q4 2024 Repligen Corp Earnings Call Transcript
Key Points
- Repligen Corp (RGEN) achieved the midpoint of its November guidance, delivering fourth-quarter revenue of $167.5 million and full-year revenue of $634.4 million, despite a $3.5 million exchange rate headwind.
- The company reported a 13% revenue growth ex-COVID in the fourth quarter compared to the previous year, driven by product differentiation and better market conditions.
- Repligen Corp (RGEN) saw strong order intake in the fourth quarter, marking the highest order intake since Q2 2022, with orders outpacing non-COVID revenue for six consecutive quarters.
- The CDMO business experienced significant growth, with sales and orders up high double digits sequentially, contributing to a similar full-year sales growth in both CDMO and pharma sectors.
- The company successfully launched several differentiated new products in 2024, including the KrosFlo RS10 RPM system and AVIPure double-stranded RNA resin, enhancing its portfolio and addressing unmet customer needs.
- Repligen Corp (RGEN) faced a $3.5 million exchange rate headwind in the fourth quarter and $5.7 million for the year, impacting overall financial performance.
- The protein segment experienced a 28% decline in revenue for the full year, attributed to a reset year with OEM ligand demand down to minimum levels.
- China was identified as a key headwind in 2024, with sales expected to remain flat compared to 2024, impacting overall regional performance.
- The company incurred approximately $45 million in non-recurring restructuring and inventory-related charges in the fourth quarter, primarily due to non-cash inventory write-offs.
- Repligen Corp (RGEN) reported a decrease in adjusted fully diluted earnings per share for the fourth quarter, down to $0.44 from $0.48 in the same period in 2023.
Good day, ladies and gentlemen, and welcome to Repligen Corporation's fourth quarter of 2024 earnings conference call. My name is MJ, and I will be your coordinator. (Operator Instructions)
I would now like to turn the call over to your host for today's call, Sondra Newman, Head of Investor Relations. Please go ahead.
Thank you and welcome to our fourth quarter of 2024 report. On this call, we will cover business highlights and financial performance for the 3- and 12-month periods ending December 31, 2024. And we'll provide financial guidance for the full year 2025.
Joining us on the call today are Repligen's President and Chief Executive Officer, Olivier Loeillot; and our Chief Financial Officer, Jason Garland. As a reminder, the forward-looking statements that we make during this call, including those regarding our business goals and expectations for the financial performance of the company, are subject to risks and uncertainties that may cause actual events or results to differ.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
